INT242210

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 7
Disease Relevance 3.59
Pain Relevance 0.61

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (GLP1R) plasma membrane (GLP1R) signal transducer activity (GLP1R)
Anatomy Link Frequency
plasma 4
liver 2
stomach 2
GLP1R (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 52 99.46 Very High Very High Very High
abdominal pain 7 94.32 High High
Central nervous system 4 9.72 Low Low
ischemia 12 5.00 Very Low Very Low Very Low
Inflammation 10 5.00 Very Low Very Low Very Low
Neuropeptide 8 5.00 Very Low Very Low Very Low
adenocard 6 5.00 Very Low Very Low Very Low
headache 6 5.00 Very Low Very Low Very Low
potassium channel 4 5.00 Very Low Very Low Very Low
cva 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Vomiting 31 99.04 Very High Very High Very High
Diabetes Mellitus 419 98.88 Very High Very High Very High
Sprains And Strains 2 98.36 Very High Very High Very High
Diarrhoea 4 95.56 Very High Very High Very High
Abdominal Pain 7 94.32 High High
Gastric Motility Disorder 1 92.60 High High
Myocardial Infarction 57 85.72 High High
Hypoglycemia 85 83.60 Quite High
Coronary Artery Disease 4 82.48 Quite High
Hyperglycemia 36 80.48 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
An adenoviral vectored gene therapeutic option transfecting the GLP-1 gene into hepatozytes of a diabetic rat strain showed positive effects in one study, but because of the present difficulties and safety concerns using these methods in humans, this theoretical option has not been followed up so far [19].
Positive_regulation (transfecting) of Gene_expression (transfecting) of GLP-1 associated with diabetes mellitus and sprains and strains
1) Confidence 0.58 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.58 Pain Relevance 0.13
Also, subcutaneous injections of GLP-1 do not lead to a sufficiently high and long-lasting elevation of GLP-1 concentrations to use native GLP-1 as a practical therapeutic agent.
Positive_regulation (lead) of Gene_expression (injections) of GLP-1
2) Confidence 0.42 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.67 Pain Relevance 0.10
DPP-4 inhibition increases not only prandial but also fasting levels of active GLP-1 and results in an overall increase in GLP-1 levels with maintenance of circadian rhythm throughout the day.
Positive_regulation (increase) of Gene_expression (levels) of GLP-1
3) Confidence 0.31 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.13 Pain Relevance 0
Through preventing the rapid degradation of incretin hormones, DPP-4 inhibitors result in postprandial increases in levels of biologically active intact GLP-1 and reduce glucose production from the liver by inhibition of glucagon from the ?
Positive_regulation (increases) of Gene_expression (levels) of GLP-1 in liver
4) Confidence 0.31 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.07 Pain Relevance 0
GLP-1 secretion may be impaired in T2DM, and GLP-1 analogs and agonists and DPP-4 inhibitors that increase endogenous GLP-1 production have the advantage that their effect on insulin secretion depends on plasma glucose concentration.
Positive_regulation (increase) of Gene_expression (production) of GLP-1 in plasma associated with diabetes mellitus and agonist
5) Confidence 0.07 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2515417 Disease Relevance 0.65 Pain Relevance 0.10
GLP-1 secretion may be impaired in T2DM, and GLP-1 analogs and agonists and DPP-4 inhibitors that increase endogenous GLP-1 production have the advantage that their effect on insulin secretion depends on plasma glucose concentration.
Positive_regulation (endogenous) of Gene_expression (production) of GLP-1 in plasma associated with diabetes mellitus and agonist
6) Confidence 0.07 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2515417 Disease Relevance 0.65 Pain Relevance 0.10
Since sitagliptin increases intact GLP-1 and GIP levels by 2- to 3-fold [2,18], certain GI adverse experiences were pre-specified for statistical analysis (including diarrhea, nausea, vomiting and abdominal pain [including upper and lower abdominal pain and abdominal/stomach discomfort]) in the sitagliptin development program.
Positive_regulation (increases) of Gene_expression (levels) of GLP-1 in stomach associated with abdominal pain, diarrhoea and vomiting
7) Confidence 0.07 Published 2008 Journal BMC Endocr Disord Section Body Doc Link PMC2605739 Disease Relevance 0.84 Pain Relevance 0.19

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox